Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.28 -0.1  -2.6%

Last Trade - 09/04/21

Sector
Industrials
Size
Small Cap
Market Cap £164.3m
Enterprise Value £153.0m
Revenue £2.71m
Position in Universe 764th / 1831

BRIEF-Bioporto Plans Clinical Evaluation Of Test For Rapid Detection Of Covid-19 Virus

Thu 17th September, 2020 8:46am
Sept 17 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO PLANS INITIAL CLINICAL EVALUATION OF
GRAD-BASED
TEST FOR RAPID DETECTION OF COVID-19 VIRUS
    * PRELIMINARY ANALYTICAL STUDIES OF NEWLY CREATED SARS-COV-2
ANTIBODIES, FOR DETECTION OF ACTIVE VIRUS, HAVE SHOWN PROMISING
RESULTS IN TESTING AGAINST HEAT-INACTIVATED VIRUS
    * INTENDS TO REQUEST AN EMERGENCY USE AUTHORIZATION (EUA)
FROM US
FOOD AND DRUG ADMINISTRATION (FDA) AND TO APPLY FOR CE MARK,
WHICH COULD LEAD TO PRODUCT LAUNCH BEFORE END OF YEAR.
    * ANNOUNCEMENT DOES NOT ALTER BIOPORTO'S FINANCIAL GUIDANCE
FOR
2020

Source text for Eikon:  ID:nGNEb5RDXy 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.